Literature DB >> 11705127

The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.

A McGuire1, D E Irwin, P Fenn, A Gray, P Anderson, A Lovering, A MacGowan.   

Abstract

INTRODUCTION: Chronic Bronchitis is a serious and costly health problem. Prevalence is estimated at 45 per 10,000 persons in the United Kingdom. Approximately 120,000 Pounds would be saved for every 100 hospital admissions avoided. A reduction in acute exacerbations of chronic bronchitis (AECB), treatment failures, and subsequent hospital admission could have a significant impact on the burden of AECB borne by secondary care facilities in the UK National Health Service (NHS).
OBJECTIVE: The aim of this study is to provide an economic assessment of the direct cost to the health care system associated with the management of chronic bronchitis and its acute exacerbations.
DESIGN: A prevalence-based, excess-cost-of-illness analysis is undertaken from the perspective of the UK NHS. Disease prevalence data, primary health care resource utilization, hospital inpatient and outpatient resource utilization, and costs of health care were taken from a variety of data sources, including a large UK national survey of general practice (GP) consultations, the General Practice Research Database, a survey from a single NHS hospital trust, and the national health-care resource and cost statistics.
RESULTS: From 1994 to 1995, approximately 233,000 cases of chronic bronchitis were detected in the persons aged 45 and older in the United Kingdom. Prevalence peaked at 204 per 10,000 in the group of subjects aged 75 to 84 years. During that same period, the total excess cost of primary care associated with AECB was calculated at 35.7 million Pounds. The largest component of primary care costs was the excess cost of all prescription medicines, which totaled 27.8 million Pounds. The excess cost attributed to antibacterial and respiratory prescription medications alone was estimated at 9 million Pounds. Excess costs attributed to GP consultations and hospital emergency room visits were 6.5 million Pounds and 1.3 million Pounds, respectively. The excess costs arising from inpatient hospital episodes included 8.3 million Pounds for hospital admissions, 660,000 Pounds for outpatient costs, and 225,000 Pounds for day care.
CONCLUSIONS: These results suggest that improving the management of AECB with the objective of reducing the number of AECB treatment failures and the associated hospital admissions could significantly reduce expenditures by the UK NHS.

Entities:  

Mesh:

Year:  2001        PMID: 11705127     DOI: 10.1046/j.1524-4733.2001.45049.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  17 in total

Review 1.  The general practice research database: role in pharmacovigilance.

Authors:  Louise Wood; Carlos Martinez
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

3.  Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use.

Authors:  Stephen Morris; Pippa Anderson; Debra E Irwin
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  The costs of breast cancer prior to and following diagnosis.

Authors:  Steven Broekx; Elly Den Hond; Rudi Torfs; Anne Remacle; Raf Mertens; Thomas D'Hooghe; Patrick Neven; Marie-Rose Christiaens; Steven Simoens
Journal:  Eur J Health Econ       Date:  2010-03-20

Review 5.  COPD exacerbations .1: Epidemiology.

Authors:  G C Donaldson; J A Wedzicha
Journal:  Thorax       Date:  2006-02       Impact factor: 9.139

6.  Lower respiratory tract infections: impact on the workplace.

Authors:  Howard Birnbaum; Melissa Morley; Stephanie Leong; Paul Greenberg; Gene Colice
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 7.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  Pharmacoeconomics in COPD: lessons for the future.

Authors:  Helen J Starkie; Andrew H Briggs; Mike G Chambers
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Airways inflammation and treatment during acute exacerbations of COPD.

Authors:  Erik Bathoorn; Huib Kerstjens; Dirkje Postma; Wim Timens; William MacNee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation.

Authors:  Erik Bathoorn; Jeroen J W Liesker; Dirkje S Postma; Gerard H Koëter; Marco van der Toorn; Sicco van der Heide; H Alec Ross; Antoon J M van Oosterhout; Huib A M Kerstjens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.